Sylvester Comprehensive Cancer Center

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20170529

    SDG: Breast Cancer
    Disease Site(s):

    Breast,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Lymphoid Leukemia,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma,Multiple

    Sponsor: ASCO

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190822 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:
    RCemailImg Alexander Diaz
    RCphone 3052436855

    IRB: 20190822

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Ovary,Prostate,Stomach,Colon,Rectum,Pancreas,Other Digestive Organ,Lung,Melanoma, skin

    Sponsor: NGM BIOPHARMACEUTICALS

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

    Eligibility Criteria - NCT04068896 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190823 - Huang Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Harshita Gahankari
    RCphone 3052430959

    IRB: 20190823

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Ovary,Non-Hodgkin Lymphoma,Hodgkin Lymphoma,Lung

    Sponsor: Plexxikon

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1b/2a Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Advanced Malignancies

    Eligibility Criteria - NCT03297424 *This information has been extracted from " www.clinicaltrials.gov"

  • ADP-0000-001 - Ikpeazu, Chukwuemeka

  • Investigator:
    Chukwuemeka Ikpeazu
    RCname Email

    Coordinator:
    RCemailImg Carla Munevar
    RCphone 9542101170

    IRB: 20150874

    SDG: Thoracic Oncology
    Disease Site(s):

    Lung

    Sponsor: Adaptimmune

    Enrolling Sites:

    Title:

    A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies

    Eligibility Criteria - NCT02636855 *This information has been extracted from " www.clinicaltrials.gov"

  • BTCRC-LUN17-127 - Ikpeazu, Chukwuemeka

  • Investigator:
    Chukwuemeka Ikpeazu
    RCname Email

    Coordinator:
    RCemailImg Chinar Singh
    RCphone 3052438237

    IRB: 20181092

    SDG: Thoracic Oncology
    Disease Site(s):

    Lung

    Sponsor: BTCRC

    Enrolling Sites:

    Sylvester

    Title:

    BTCRC-LUN17-127 : A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients with Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-127

    Eligibility Criteria - NCT03575793 *This information has been extracted from " www.clinicaltrials.gov"

  • QUILT-3.055 - Ikpeazu, Chukwuemeka

  • Investigator:
    Chukwuemeka Ikpeazu
    RCname Email

    Coordinator:
    RCemailImg Carla Munevar
    RCphone 9542101170

    IRB: 20181197

    SDG: Thoracic Oncology
    Disease Site(s):

    Lung

    Sponsor: ALTOR BIOSCIENCE CORP

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    CA-ALT-803-02-17: QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy

    Eligibility Criteria - NCT03228667 *This information has been extracted from " www.clinicaltrials.gov"

  • IM-202 - Lockhart, Albert

  • Investigator:
    Albert Lockhart
    RCname Email

    Coordinator:
    RCemailImg Ximena Marincic-Sanchez
    RCphone 3052439200

    IRB: 20180968

    SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Stomach,Lung

    Sponsor: IAB

    Enrolling Sites:

    Sylvester

    Title:

    IM-202 : A Randomized, Open-Label, Multicenter, Phase 1b/2 Trial Evaluating The Safety And Efficacy Of Intratumorally-Administered Ilixadencel in Combination With Checkpoint Inhibitor (CPI) in Advanced Cancer Subjects Who are Candidates ForCPI Therapy

    Eligibility Criteria - NCT03735290 *This information has been extracted from " www.clinicaltrials.gov"

  • 1381.2 - Lockhart, Albert

  • Investigator:
    Albert Lockhart
    RCname Email

    Coordinator:
    RCemailImg Alexander Diaz
    RCphone 3052436855

    IRB: 20190219

    SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Bladder,Stomach,Lung

    Sponsor: BOEHRINGER INGELHEIM

    Enrolling Sites:

    Sylvester

    Title:

    1381.2: An Open Label, Phase I Dose-Finding Study Of BI 754111 In Combination With BI 754091 In Patients With Advanced Solid Cancers Followed By Expansion Cohorts At The Selected Dose Of The Combination In Patients With Non-Small Cell Lung Cancer And Other Solid Tumors

    Eligibility Criteria - NCT03156114 *This information has been extracted from " www.clinicaltrials.gov"

  • A081105/ALCHEMIST - Lopes, Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    Coordinator:
    RCemailImg Maria Pardo
    RCphone 3052437036

    IRB: 20140690

    SDG: Thoracic Oncology
    Disease Site(s):

    Lung

    Sponsor: Alliance for Clinical Trials in Oncology

    Enrolling Sites:

    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    A081105: Randomized double blind placebo controlled study of Erlontinib or placebo in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC)

    Eligibility Criteria - NCT02193282 *This information has been extracted from " www.clinicaltrials.gov"

  • BLU-667-1101 - Lopes, Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    Coordinator:
    RCemailImg Harshita Gahankari
    RCphone 3052430959

    IRB: 20170957

    SDG: Thoracic Oncology
    Disease Site(s):

    Thyroid,Other Endocrine System,Colon,Lung

    Sponsor: Blueprint Medicines

    Enrolling Sites:

    Sylvester

    Title:

    BLU-667-1101: A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors

    Eligibility Criteria - NCT03037385 *This information has been extracted from " www.clinicaltrials.gov"

  • 208471 - Lopes, Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    Coordinator:
    RCemailImg Maria Pardo
    RCphone 3052437036

    IRB: 20180862

    SDG: Thoracic Oncology
    Disease Site(s):

    Lung

    Sponsor: GLAXOSMITHKLINE GROUP

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    208471: A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination with Pembrolizumab in HLA-A2+ Participants with NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer

    Eligibility Criteria - NCT03709706 *This information has been extracted from " www.clinicaltrials.gov"

  • 208750 - Lopes, Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    Coordinator:
    RCemailImg Maria Pardo
    RCphone 3052437036

    IRB: 20190078

    SDG: Thoracic Oncology
    Disease Site(s):

    Lung

    Sponsor: GLAXOSMITHKLINE GROUP

    Enrolling Sites:

    Sylvester

    Title:

    208750: Long Term Follow-Up of Participants Exposed to GSK3377794 (NY-ESO-1C259T), a Genetically Engineered NY-ESO-1 Specific T Cell Receptor

    Eligibility Criteria - NCT03391778 *This information has been extracted from " www.clinicaltrials.gov"

  • MS200647_0005 - Lopes, Gilberto

  • Investigator:
    Gilberto Lopes
    RCname Email

    Coordinator:

    IRB: 20190361

    SDG: Thoracic Oncology
    Disease Site(s):

    Lung

    Sponsor: EMD

    Enrolling Sites:

    Sylvester

    Title:

    A Multicenter, Double Blind, Randomized,Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants with UnresectableStage III Non-small Cell Lung Cancer

    Eligibility Criteria - NCT03840902 *This information has been extracted from " www.clinicaltrials.gov"

  • VYR-VSV2-101 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone 3052437387

    IRB: 20170023

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Lung,Melanoma, skin,Kaposis sarcoma

    Sponsor: VYRIAD

    Enrolling Sites:

    Sylvester

    Title:

    Phase I Trial of Intratumoral Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and human interferon beta (VSV-IFN▀-NIS), in Patients with Refractory Solid Tumors

    Eligibility Criteria - NCT02923466 *This information has been extracted from " www.clinicaltrials.gov"

  • CPI-006-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone 3052437387

    IRB: 20180279

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Cervix Uteri,Corpus Uteri,Prostate,Bladder,Kidney,Non-Hodgkin Lymphoma,Lymphoid Leukemia,Colon,Rectum,Pancreas,Lung,Bones and Joints,Soft Tissue

    Sponsor: CP

    Enrolling Sites:

    Sylvester

    Title:

    CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

    Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"

  • C3851001 - Perez, Cesar

  • Investigator:
    Cesar Perez
    RCname Email

    Coordinator:
    RCemailImg Ximena Marincic-Sanchez
    RCphone 3052439200

    IRB: 20190114

    SDG: Stomach and Esophageal Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Cervix Uteri,Other Endocrine System,Lung

    Sponsor: PFIZER

    Enrolling Sites:

    Sylvester

    Title:

    C3851001: A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, and Pharmacodynamics Of Escalating Doses Of PF-06939999 (Prmt5 Inhibitor) In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer, Head And Neck Squamous Cell Carcinoma, Esophageal Cancer, Endometrial Cancer, CervicalCancer And Bladder Cancer

    Eligibility Criteria - NCT03854227 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC-095 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    Coordinator:
    RCemailImg Sarah Lam
    RCphone 3052437586

    IRB: 20160656

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Other Hematopoietic,Anus,Lung

    Sponsor: AMC

    Enrolling Sites:

    Sylvester

    Title:

    A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors

    Eligibility Criteria - NCT02408861 *This information has been extracted from " www.clinicaltrials.gov"

  • EMR100036-002 - Samuels, Michael

  • Investigator:
    Michael Samuels
    RCname Email

    Coordinator:
    RCemailImg Chinar Singh
    RCphone 3052438237

    IRB: 20160382

    SDG: Head and Neck Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Breast,Cervix Uteri,Stomach,Lung

    Sponsor: EMD

    Enrolling Sites:

    Sylvester

    Title:

    An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination with Radiotherapy in Patients with Advanced Solid Tumors

    Eligibility Criteria - NCT02516813 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Slomovitz, Brian

  • Investigator:
    Brian Slomovitz
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20150671

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Corpus Uteri,Ovary,Other Female Genital,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma

    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    Molecular Analysis for Therapy Choice (MATCH)

    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190673 - Valdes Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Ximena Marincic-Sanchez
    RCphone 3052439200

    IRB: 20190673

    SDG: Breast Cancer
    Disease Site(s):

    Esophagus,Breast,Ovary,Other Female Genital,Kidney,Stomach,Colon,Lung

    Sponsor: MTEM

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors

    Eligibility Criteria - NCT04029922 *This information has been extracted from " www.clinicaltrials.gov"

  • NRG-LU002 - Yechieli, Raphael

  • Investigator:
    Raphael Yechieli
    RCname Email

    Coordinator:
    RCemailImg Lilly Sanchez
    RCphone 3052430974

    IRB: 20180550

    SDG: Thoracic Oncology
    Disease Site(s):

    Lung

    Sponsor: NRG

    Enrolling Sites:

    Deerfield
    Sylvester

    Title:

    NRG-LU002: Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

    Eligibility Criteria - NCT03137771 *This information has been extracted from " www.clinicaltrials.gov"